Modification of feeding behavior
View Patent ↗Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.
1. A method for decreasing calorie intake, food intake or appetite, in a human subject in need thereof, comprising peripherally administering prior to a meal to said subject PYY 3-36 (SEQ ID NO:334) in a dose of from 5 to 100 nmoles per 70 to 75 kg body weight of said subject.
2. A method for decreasing calorie intake, food intake or appetite, in a human subject in need thereof, comprising peripherally administering prior to a meal to said subject PYY 3-36 (SEQ ID NO:334) in a dosage of from about 45 to about 135 pmol per kilogram body weight of said subject.
3. The method of claim 2 , comprising administering PYY 3-36 (SEQ ID NO:334) in a dosage of about 72 pmol per kilogram body weight of said subject.
4. The method of claim 1 , comprising peripherally administering PYY 3-36 (SEQ ID NO:334) to said subject at least about 30 minutes prior to a meal.
5. The method of claim 1 , further comprising administering an additional appetite suppressant to said subject.
6. The method of claim 1 , wherein said PYY 3-36 (SEQ ID NO:334) is administered to said subject in an amount effective to decrease calorie intake, food intake or appetite for a period of up to about 12 hours.
7. The method of claim 1 , wherein the subject is overweight.
8. A method for treating obesity in a human subject in need of treatment comprising peripherally administering prior to a meal to said subject PYY 3-36 (SEQ ID NO:334) in a dose of from 5 to 100 nmoles per 70-75 kg body weight of said subject.
9. The method of claim 1 or 8 comprising administering PYY 3-36 (SEQ ID NO:334) in a dose of from 5 to 90 nmoles per 70-75 kg body weight of said subject to said subject.
10. The method of claim 1 or 8 comprising administering PYY 3-36 (SEQ ID NO:334) in a dose of from 5 to 80 nmoles per 70-75 kg body weight of said subject to said subject.
11. The method of claim 1 , comprising administering said PYY 3-36 (SEQ ID NO:334) to said subject in a sustained or depot preparation.
12. The method of claim 1 comprising administering a dose of PYY 3-36 (SEQ ID NO:334) of from 5 to 50 nmol per 70-75 kg body weight of said subject to the subject.
13. The method of claim 5 , wherein the additional appetite suppressant is selected from the group consisting of amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramine, and fluoxetine.
14. The method of claim 1 or 8 comprising administering said PYY 3-36 (SEQ ID NO:334) modified by amidation, glycosylation, acylation, sulfation, phosphorylation, cyclisation, lipidisation or pegylation.
15. A method for decreasing calorie intake, food intake or appetite, in a human subject in need thereof, comprising administering prior to a meal to said subject PYY 3-36 (SEQ ID NO:334) in a dose of from 5 to 100 nmoles per 70 to 75 kg body weight of said subject by a rectal, intravenous, intramuscular, intranasal, intraperitoneal, intravaginal, transmucosal, sublingual or buccal route, or by pulmonary inhalation.
16. The method of claim 1 or 8 wherein the PYY 3-36 (SEQ ID NO:334) is in the form of a controlled release preparation.
17. A method for treating obesity in a human subject in need thereof, comprising administering prior to a meal to said subject PYY 3-36 (SEQ ID NO:334) in a dose of from 5 to 100 nmoles per 70 to 75 kg body weight of said subject by a rectal, intravenous, intramuscular, intranasal, intraperitoneal, intravaginal, transmucosal, sublingual or buccal route, or by pulmonary inhalation.
18. The method of claim 15 or 17 comprising administering said PYY 3-36 (SEQ ID NO:334) modified by amidation, glycosylation, acylation, sulfation, phosphorylation, cyclisation, lipidisation or pegylation.